Recursion Pharmaceuticals Inc.

12/09/2024 | Press release | Distributed by Public on 12/09/2024 17:31

Recursion Reports Interim Phase 1 Clinical Data for REC 617 Monotherapy, a Potential Best in Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.